Publication / Source: Bioanalysis 3(11)
Authors: Korfmacher W
“I propose that we are entering a new era for drug-discovery bioanalysis. I believe that we are already starting to have a true paradigm shift on how we perform our quantitative assays in support of lead optimization efforts.”
The use of HPLC combined with MS/MS has been the state-of-the-art analytical tool for drug-discovery bioanalysis (BA) for almost two decades [1–3]. Over that time, the HPLC systems have improved and evolved, with perhaps the biggest change in recent years when UPLC became commercially available [4–6]. While MS/MS systems have also improved over those two decades, the basic principle of using selected reaction monitoring (SRM) for the analytical detection of the analyte of interest has remained the same [1–3].